Back
Fidelity Disruptive Communications ETF Vs. Sarepta Therapeutics Industry Stock Comparison
Buy
63
FDCF
Fidelity Disruptive Communications ETF
Last Price:
38.75
Seasonality Move:
13.1%
Sell
49
SRPT
Sarepta Therapeutics
Last Price:
130.47
Seasonality Move:
14.88%
Buy
63
Fidelity Disruptive Communications ETF (FDCF)
is a Buy
Is Fidelity Disruptive Communications ETF a Buy, Sell or Hold?
- The current Fidelity Disruptive Communications ETF [FDCF] share price is $38.86. The Score for FDCF is 63, which is 26% above its historic median score of 50, and infers lower risk than normal.
- FDCF is currently trading in the 60-70% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
49
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $130.50. The Score for SRPT is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
FDCF Stock Price Chart
What is Fidelity Disruptive Communications ETF's stock price today?
-
The Fidelity Disruptive Communications ETF share price today is $38.86
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and FDCF is experiencing slight buying pressure.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $130.50
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
FDCF Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.29 | Buy |
| Relative Strength Index (14 RSI): | 60.6 | Buy |
| Chaikin Money Flow: | 1597 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (37.71 - 38.79) | Buy |
| Bollinger Bands (100): | (34.05 - 37.97) | Buy |
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -2.3 | Sell |
| Relative Strength Index (14 RSI): | 64.59 | Buy |
| Chaikin Money Flow: | 3149400 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (111.02 - 128.88) | Buy |
| Bollinger Bands (100): | (119.18 - 142.3) | Sell |
FDCF Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 38.35 | Buy |
| 20-day SMA: | 38.4 | Buy |
| 50-day SMA: | 37.68 | Buy |
| 200-day SMA: | 34.4 | Buy |
| 8-day EMA: | 38.54 | Buy |
| 20-day EMA: | 38.32 | Buy |
| 50-day EMA: | 37.54 | Buy |
| 200-day EMA: | 34.33 | Buy |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 112.07 | Buy |
| 20-day SMA: | 117.27 | Buy |
| 50-day SMA: | 121.92 | Buy |
| 200-day SMA: | 129.99 | Buy |
| 8-day EMA: | 116.28 | Buy |
| 20-day EMA: | 117.14 | Buy |
| 50-day EMA: | 121.91 | Buy |
| 200-day EMA: | 125.98 | Buy |
Fidelity Disruptive Communications ETF Earnings Growth & FDCF Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.87 per share, a decrease next quarter of $0.00 per share, an increase this year of $4.84 per share, and an increase next year of $8.76 per share.
Fidelity Disruptive Communications ETF Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Sarepta Therapeutics Technical Analysis
| Nov 13 | Nov 14 | Nov 15 | Nov 18 | Nov 19 | Nov 20 | Nov 21 | Nov 22 | Nov 25 | Nov 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov | ||||||||||
| 13 | 14 | 15 | 18 | 19 | 20 | 21 | 22 | 25 | 26 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||